Amneal Pharmaceuticals (AMRX) Inventory Average (2018 - 2026)

Amneal Pharmaceuticals' Inventory Average history runs 9 years deep, the most recent figure standing at $624.0 million for Q1 2026.

• On a quarterly basis, Inventory Average rose 2.8% year-over-year to $624.0 million in Q1 2026; TTM through Mar 2026 was $624.0 million, a 2.8% increase from a year earlier, with the FY2025 full-year figure at $609.4 million, up 2.09% from the prior year.
• Inventory Average climbed to $624.0 million in Q1 2026 per AMRX's latest filing, from $610.4 million in the prior quarter.
• Across five years, Inventory Average topped out at $624.0 million in Q1 2026 and bottomed at $500.8 million in Q1 2022.
• The 5-year median for Inventory Average is $576.0 million (2024), against an average of $571.1 million.
• Across the five-year window, Inventory Average increased 8.71% in 2024 and advanced 0.99% in 2025, its largest moves.
• Year by year, Inventory Average stood at $537.3 million in 2022, then increased by 7.75% to $578.9 million in 2023, then increased by 4.4% to $604.4 million in 2024, then advanced by 0.99% to $610.4 million in 2025, then gained by 2.22% to $624.0 million in 2026.
• Per Business Quant, the three latest AMRX Inventory Average figures stand at $624.0 million (Q1 2026), $610.4 million (Q4 2025), and $611.7 million (Q3 2025).